Skip to content


  • Poster presentation
  • Open Access

Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck

  • 1,
  • 2,
  • 2,
  • 1,
  • 1, 3,
  • 1,
  • 1,
  • 1,
  • 4,
  • 1,
  • 1,
  • 5 and
  • 1, 3
Journal for ImmunoTherapy of Cancer20131 (Suppl 1) :P262

  • Published:


  • Squamous Cell Carcinoma
  • Oral Cavity
  • Cell Infiltrate
  • Autologous Tumor
  • Autologous Tumor Cell

Squamous cell carcinoma of the head and neck (HNSCC) arises in the oral cavity, oropharynx, larynx or hypopharynx, and is the 6th leading cause of cancer by incidence worldwide. Approximately 600,000 cases arise each year, and only 40-50% of these patients will survive for 5 years.7 HNSCC can express PD-L1 and suppressive factors that interfere with the differentiation and activation of dendritic cells and effector function of T cells. Similar to observations in other malignancies, CD8 effector T cell infiltration or transcriptional signature consistent with an ongoing T cell response is associated with prolonged survival. This suggests that HNSCC lacking a T cell infiltrate may benefit from immune interventions that induce and/or augment a tumor-specific immune response. To develop a strategy to address this problem we have created a HNSCC tumor bank that is cryopreserving enzymatically isolated viable cells from resected tumors (39 specimens). We are also attempting to develop primary cell lines (4 lines established) and are isolating tumor-infiltrating lymphocytes from these specimens. We are looking to compare immunohistochemical, flowcytometric and functional analyses of these specimens. Consistent with previous studies, results document that isolated TIL secrete IFN-γ when stimulated with their autologous tumor cells (n=2). Since a central aim of these studies is to develop a strategy to create therapeutic immunity in patients lacking T cell infiltrates, we plan to investigate which antigens are recognized and whether, antigens present in a novel DRibble vaccine, that expresses antigens common to HNSCC, are recognized by these TIL. This may provide a strategy to monitor anti-tumor immunity in these patients and possibly provide an antigen source for combination immunotherapy of patients with HNSCC.

Authors’ Affiliations

Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA
Oral, Head and Neck Cancer Program and Clinic, Providence Cancer Center, Portland, OR, USA
Molecular Microbiology and Immunology, OHSU, Portland, OR, USA
UbiVac, Portland, OR, USA
Department of Pathology, Providence Cancer Center, Portland, OR, USA


© Moudgil et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.